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Abstract
Background: Platinum-based drugs, such as cisplatin and oxaliplatin, are well-known for inducing chronic sensory
neuropathies but their acute and motor neurotoxicities are less well characterised. Use was made of nerve
conduction studies and needle electromyography (EMG) to assess motor nerve excitability in cancer patients
during their first treatment cycle with platinum-based chemotherapy in this study.
Methods: Twenty-nine adult cancer patients had a neurophysiological assessment either before oxaliplatin plus
capecitabine, on days 2 to 4 or 14 to 20 after oxaliplatin plus capecitabine, or on days 2 to 4 after carboplatin plus
paclitaxel or cisplatin, undertaken by a neurophysiologist who was blinded to patient and treatment details.
Patients completed a symptom questionnaire at the end of the treatment cycle.
Results: Abnormal spontaneous high frequency motor fibre action potentials were detected in 100% of patients
(n = 6) and 72% of muscles (n = 22) on days 2 to 4 post-oxaliplatin, and in 25% of patients (n = 8) and 13% of
muscles (n = 32) on days 14 to 20 post-oxaliplatin, but in none of the patients (n = 14) or muscles (n = 56) tested
prior to oxaliplatin or on days 2 to 4 after carboplatin plus paclitaxel or cisplatin. Repetitive compound motor
action potentials were less sensitive and less specific than spontaneous high frequency motor fibre action
potentials for detection of acute oxaliplatin-induced motor nerve hyperexcitability but were present in 71% of
patients (n = 7) and 32% of muscles (n = 32) on days 2 to 4 after oxaliplatin treatment. Acute neurotoxicity
symptoms, most commonly cold-induced paraesthesiae and jaw or throat tightness, were reported by all patients
treated with oxaliplatin (n = 22) and none of those treated with carboplatin plus paclitaxel or cisplatin (n = 6).
Conclusions: Abnormal spontaneous high frequency motor fibre activity is a sensitive and specific endpoint of
acute oxaliplatin-induced motor nerve hyperexcitability, detectable on EMG on days 2 to 4 post-treatment.
Objective EMG assessment of motor nerve excitability could compliment patient-reported symptomatic endpoints
of acute oxaliplatin-induced neurotoxicity in future studies.
Background
Cancer chemotherapy based on cisplatin, carboplatin
and oxaliplatin, usually combined with radiation, capeci-
tabine, paclitaxel or other agents, is the mainstay of
treatment for many cancer patients, including those
with lung, colorectum, stomach, head and neck, cervix,
oesophagus, bladder, ovary and testis cancer [1].
However, platinum-induced chronic neuro-sensory toxi-
cities are treatment-limiting, in particular glove and
stocking distal paraesthesiae and dysesthesiae with loss
of tendon reflexes and peripheral sensation, and ototoxi-
city with tinnitus and hearing loss [2-4]. Neuro-sensory
toxicities typically develop after repeated dosing, pro-
gress cumulatively with continued treatment and persist
long beyond the completion of treatment. In addition,
oxaliplatin has been reported to cause a distinct acute
and reversible neurotoxicity syndrome with motor
symptoms [3], which has not been reported with other
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sensory toxicities of platinum-based drugs are well
known, their acute and motor neurotoxicity are less well
characterised.
In a previous study of cancer patients treated with
oxaliplatin [5,6], striking neurophysiological abnormal-
ities were demonstrated suggesting a state of acute per-
ipheral nerve hyperexcitability due to altered axonal ion
channel activity. These neurophysiological abnormalities
included repetitive compound motor action potentials
(CMAPs) during nerve conduction studies after a single
electrical stimulus following the main CMAP, and high
frequency motor fibre action potentials on needle elec-
tromyography (EMG) that occurred spontaneously and
upon needle insertion or voluntary muscle contraction.
Since these original reports, few or no subsequent stu-
dies by other groups have independently confirmed the
occurrence of repetitive CMAPs and/or abnormal motor
fibre action potentials in patients treated with oxaliplatin
or other chemotherapy drugs.
In the current study, use was made of nerve conduc-
tion studies and EMG to assess motor nerve excitability
in cancer patients during their first treatment cycle of
platinum-based chemotherapy. We sought to define
clinical procedures for the objective assessment of acute
oxaliplatin-induced motor nerve hyperexcitability by
optimising the time-points and endpoints for its neuro-
physiological detection. In addition, we aimed to inde-
pendently confirm whether repetitive CMAPs and/or
abnormal motor fibre action potentials were detectable
after oxaliplatin treatment, and to obtain preliminary
evidence of their occurrence after treatment with other
platinum drugs. Neurophysiological studies are inher-
ently subjective as they require qualitative interpretation.
To reduce observer bias in the current study, a control
group of patients was included who were tested prior to
receiving platinum-based chemotherapy and the neuro-
physiologist was blinded to patient group and treatment
details.
Methods
Patients
Eligible subjects were adult cancer patients who were
to receive standard chemotherapy with oxaliplatin
(130 mg/m
2), cisplatin (100 mg/m
2) or carboplatin
(AUC 6 mg*min/ml) alone or in combination with
other agents repeated three weekly, and who had given
written informed consent. Subjects who had previously
received platinum-based chemotherapy and those with
previous or existing peripheral neuropathy or medical
contraindications to clinical neurophysiological proce-
dures were ineligible. The study was approved by the
Auckland Ethics Committee × (Approval no AKX 04/
06/165).
Study Procedures and Groups
Study procedures included neurophysiological assess-
ment and symptom evaluation both carried out during
the first treatment cycle of platinum-based chemother-
apy. The neurophysiological assessment was carried out
once only to avoid subject drop-out, which was asso-
ciated with repeated assessments in previous studies [6].
Study patients were allocated to one of four groups
according to their treatment and the timing of their
neurophysiological assessment, as follows: group 1,
assessment prior to oxaliplat i n ;g r o u p2 ,a s s e s s m e n to n
days 2 to 4 after oxaliplatin; group 3, assessment on
days 14 to 20 after oxaliplatin, and; group 4, assessment
on days 2 to 4 after carboplatin plus paclitaxel or
cisplatin.
Neurophysiological assessment
The neurophysiological assessment included a standard
neurological examination, nerve conduction studies and
EMG, carried out by a neurology specialist (PB) who
was blinded to the patient and treatment details. To
maintain blinding, the neurologist did not take a neuro-
logical history and ensured that patients did not volun-
teer any neurological symptoms.
The neurophysiological assessment was similar to that
previously reported [5,6]. Standard nerve conduction
techniques, electrode positions and stimulation sites
were used. Limb temperature was monitored and main-
tained above 32°C. Neurophysiological testing was car-
ried out in the limbs opposite to the arm used for the
chemotherapy infusion. Sensory studies comprised sural,
radial, median and ulnar sensory nerve action potentials
(SNAPs). Motor studies were performed in median,
ulnar, peroneal and tibial nerves. The presence of repeti-
tive compound muscle action potentials (CMAPs) was
assessed in the four motor nerves tested using an F-
wave programme, with a slower sweep speed than con-
ventional CMAP recordings. EMG was performed in
first dorsal interosseous (FDIO), extensor digitorum
communis (EDC), tibialis anterior and gastrocnemius
muscles. Most patients had all 4 sensory and motor
nerve studies performed, and all 4 muscles sampled by
EMG, though a few did not have the complete set of
these tests.
A simple scoring system for increased motor unit
activity was created:
0 No abnormal motor unit activity
1 Increased insertional activity
2 Spontaneous high frequency motor unit activity with
muscle clinically at rest, with bursts lasting for duration
of less than 2 seconds
3 Spontaneous high frequency motor unit activity with
muscle clinically at rest, with bursts lasting for duration
of 2 to 5 seconds
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muscle clinically at rest, with bursts lasting for duration
of more than 5 seconds
Symptom evaluation
Patients completed a short symptom questionnaire,
immediately before their neurophysiological assessment
and at the end of the first treatment cycle, documenting
the presence, absence, severity, onset time and duration
of jaw or throat tightness, perioral paraesthesiae, muscle
cramps, cold-induced paraesthesiae, glove and stocking
numbness and tingling, infusional arm discomfort, loss
of sensation of breathing, visual disturbance and any
other neurotoxicity symptoms. The neurologist (PB)
remained blinded to the result of this questionnaire.
Symptom data from one oxaliplatin patient was unavail-
able because of sudden cardiac death.
Data handling
A group size of 6 to 8 subjects was considered adequate
to provide sufficient data for each time point and treat-
ment group to give a reasonable estimate of the propor-
tion of patients with motor nerve hyperexcitability. Data
were analysed using descriptive statistics and reported
as the number and proportion of patients, muscles and
nerves affected by motor nerve hyperexcitability for
each group. The standard error of each proportion was
calculated as follows; standard error = √p(1-p)/n), where
p is proportion and n is sample size. No formal evalua-
tion of the statistical significance of differences between
groups was planned or carried out. Test sensitivity was
calculated from the number of patients, muscles or
nerves displaying motor nerve hyperexcitability
expressed as a percentage of the total number of
patients, muscles or nerves tested on days 2 to 4 after
oxaliplatin. Test specificity was calculated as the number
of patients, muscles or nerves not displaying motor
nerve hyperexcitability expressed as a percentage of the
total number of patients, muscles or nerves tested
before oxaliplatin or on days 2 to 4 after carboplatin
plus paclitaxel or cisplatin.
Results
Patients and Treatment
The study population (Table 1) included a total of 29
patients (22 males and 7 females) ranging in age from
28 to 79 years (median 62 years), and cancer diagnoses
included colorectal cancer Dukes C (13 patients), color-
ectal cancer metastatic (10 patients), head and neck can-
cer (4 patients) and non-small cell lung cancer (2
patients). All patients had ECOG performance status of
0 or 1. Eleven patients had one or more co-morbidities,
most commonly hypertension (6 patients) or hypercho-
lesterolaemia (3 patients). Seven patients had received
prior chemotherapy, one regimen in 5 patients and two
regimens in 2 patients, including 5-fluorouracil plus foli-
nic acid (4 patients), single agent capecitabine (3
patients) and capecitabine plus irinotecan (2 patients).
None of the patients had been previously treated with
platinum-based chemotherapy. The study was underta-
ken during the first treatment cycle of platinum-based
chemotherapy with oxaliplatin (130 mg/m
2 day 1) plus
Table 1 Patient Characteristics
Number of Patients
Age Median 62 years
Range 28 to 79 years
Gender Male 22
Female 7
Cancer Diagnosis Colorectal Dukes C 13
Colorectal Metastatic 10
Head and Neck 4
Non-Small Cell Lung Cancer 2
Co-morbidities None 18
One or more
1 11
Prior chemotherapy None 22
One or more regimens
2 7
Study Chemotherapy Oxaliplatin (130 mg/m
2) with Capecitabine (1000 to 2000 mg BID po days 1 to 14) 23
Cisplatin (100 mg/m
2)4
Carboplatin (AUC 6 mg*min/ml) with Paclitaxel (200 mg/m
2)2
1hypertension (6 patients), hypercholesterolaemia (3 patients), goitre, rheumatoid arthritis, gout, benign prostatic hypertrophy, impaired glucose tolerance,
ischaemic heart disease, polycythaemia rubra vera; renal stones, duodenal ulcer (1 patient each).
2 5-fluorouracil plus folinic acid (4 patients), single agent
capecitabine (3 patients), capecitabine plus irinotecan (2 patients).
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Page 3 of 8capecitabine (1000 to 2000 mg/m
2 bd po days 1 to 14)
[23 patients], cisplatin (100 mg/m
2) [4 patients] or car-
boplatin (AUC 6 mg*min/ml) plus paclitaxel (200 mg/
m
2) [2 patients].
Spontaneous high frequency motor unit activity
EMGs were graded according to a study-specific scale
shown in the methods section. Normal or increased
insertional motor unit activity (grades 0 or 1) was the
maximum severity grade of motor nerve hyperexcitabil-
ity in all subjects having EMG testing prior to oxalipla-
tin or after carboplatin plus paclitaxel or cisplatin. An
example of a normal EMG from a patient tested before
any treatment is shown in Fig 1A. Abnormal, sponta-
neous high frequency motor unit activity (grade 2 or
more) was found in 8 of 14 (57%) patients after oxalipla-
tin treatment but not in any other patient group (Table
2; Figure 1C). An example of an abnormal EMG show-
ing spontaneous high frequency motor unit activity in a
patient treated 46 hours earlier with oxaliplatin is shown
in Figure 1B.
Abnormal, spontaneous high frequency motor unit
activity was detected in all patients tested on days 2 to 4
after oxaliplatin (6 of 6; 100%) but in fewer patients
tested on days 14 to 20 after oxaliplatin (2 of 8; 25%)
and no patients tested prior to oxaliplatin (0 of 8; 0%),
or on days 2 to 4 after carboplatin plus paclitaxel or cis-
platin (0 of 6; 0%). Abnormal, spontaneous high fre-
quency motor unit activity was detected in most
muscles tested on days 2 to 4 after oxaliplatin (16/22;
72%) but in fewer muscles tested on days 14 to 20 after
oxaliplatin (4 of 32; 12%) and in none of the muscles
tested prior to oxaliplatin (0 of 32; 0%), or on days 2 to
4 after carboplatin plus paclitaxel or cisplatin (0 of 24;
0%).
The sensitivity of spontaneous high frequency motor
unit activity for detecting acute motor nerve hyperexcit-
ability on days 2 to 4 after oxaliplatin was 100% and
72% for patients and muscles respectively, and its speci-
ficity was 100% for both patients and muscles (Table 2).
No abnormalities in sensory nerve conduction studies
were seen.
Repetitive CMAPs
The presence of repetitive CMAPs was recorded as an
all-or-nothing phenomenon in the absence of a method
of grading the severity or extent of this abnormality.
Abnormal repetitive CMAPs were found more fre-
quently after oxaliplatin treatment but also occurred in
groups not receiving oxaliplatin (Table 2; Figure 2). An
example of a normal CMAP tracing from a patient
tested prior to any treatment is shown in Figure 2A. A
representative study showing abnormal repetitive
CMAPs from a patient tested 46 hours after treatment
with oxaliplatin is shown in Fig2B.
Repetitive CMAPs (Fig 2C) were present in most
patients tested on days 2 to 4 after oxaliplatin (5 of 7;
71%) but in fewer patients tested before oxaliplatin (1 of
8; 13%), on days 14 to 20 after oxaliplatin (2 of 8; 25%)
or on days 2 to 4 after carboplatin plus paclitaxel or
Figure 1 Spontaneous high frequency motor fibre action potentials. (A) Normal EMG at baseline; (B) EMG showing spontaneous high
frequency motor fibre action potentials 46 hrs after oxaliplatin; (C) Proportion of patients and muscles affected by spontaneous high frequency
motor fibre action potentials by time relative to chemotherapy.
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Page 4 of 8cisplatin (1 of 6; 17%). Repetitive CMAPs were present
in about one third of the nerves tested on days 2 to 4
after oxaliplatin (9 of 28; 32%) but in fewer nerves tested
before oxaliplatin (1 of 32; 3.2%), on days 14 to 20 after
oxaliplatin (3 of 31; 10%) or on days 2 to 4 after carbo-
platin plus paclitaxel or cisplatin (2 of 24; 8%).
The sensitivity of repetitive CMAPs for detecting
acute motor nerve hyperexcitability on days 2 to 4 after
oxaliplatin was 71% and 32% for patients and nerves,
respectively. The specificity of repetitive CMAPs for
detecting acute motor nerve hyperexcitability on days 2
to 4 after oxaliplatin was 86% and 95% for patients and
nerves, respectively (Table 2).
Neurotoxicity symptoms
Cold-induced paraesthesiae were reported by all patients
treated with oxaliplatin (22 of 22; 100%) with its onset
ranging from 0 to 48 hours post-treatment (median 0
Table 2 Comparison of neurophysiological endpoints of acute oxaliplatin-induced motor nerve hyperexcitability
Number of Abnormal Tests/Total
Number of Tests (%)
Spontaneous High Frequency Motor Unit
Action Potentials
Repetitive Compound Motor
Action Potentials
Before Patients 0/8 (0%) 1/8 (13%)
Oxaliplatin Muscles or
Nerves
0/32 (0%) 1/32 (3.2%)
After Oxaliplatin Patients 6/6 (100%) 5/7 (71%)
(Days 2-4) Muscles or
Nerves
16/22 (72%) 9/28 (32%)
After Oxaliplatin Patients 2/8 (25%) 2/8 (25%)
(Days 14-20) Muscles or
Nerves
4/32 (12%) 3/31 (10%)
After Other Patients 0/6 (0%) 1/6 (17%)
Platinum Drug
(Days 2-4)
Muscles or
Nerves
0/24 (0%) 2/24 (8%)
Sensitivity* Patients 100% 71%
Muscles or
Nerves
72% 32%
Specificity* Patients 100% 86%
Muscles or
Nerves
100% 95%
*For detecting oxaliplatin-induced motor nerve hyperexcitability on days 2 to 4 post-treatment
Figure 2 Repetitive compound motor action potentials (CMAPs). (A) Normal CMAPs at baseline; (B) Repetitive CMAPs 46 hrs after oxaliplatin;
(C) Proportion of patients and nerves affected by repetitive CMAPs by time relative to chemotherapy.
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Page 5 of 8hours) and duration ranging from 3 to 21 days (median
8 days). Jaw or throat tightness was reported by 15 of
22 patients (68%) treated with oxaliplatin with its onset
ranging from 0 to 26 hours post-oxaliplatin (median 2
hours) and duration ranging from < 1 to 21 days (med-
ian 6 days). Pain in the upper limb used for the oxalipla-
tin infusion was reported by 12 of 22 patients (55%)
treated with oxaliplatin but only in those receiving the
drug via peripheral vein canula and in no patients given
oxaliplatin via central venous line. Infusion arm discom-
fort came on 0 to 2 hours after oxaliplatin infusion
(median 0 hours) and lasted from less than 1 day to 19
days (median 7.5 days). Other symptoms reported by
oxaliplatin-treated patients included glove and stocking
paraesthesiae unrelated to cold exposure (8 patients),
muscle cramps (4 patients), transient change in vision (2
patients) and shortness of breath (1 patient).
None of the patients treated with carboplatin plus
paclitaxel or cisplatin reported cold-induced paraesthe-
siae, jaw or throat tightness, infusion arm discomfort,
glove and stocking paraesthesiae unrelated to cold expo-
sure, muscle cramps, transient change in vision or short-
ness of breath.
Discussion
In this study, we showed that abnormal, spontaneous
high frequency motor unit action potentials were a sen-
sitive and specific endpoint of acute oxaliplatin-induced
motor nerve hyperexcitability. These abnormal, sponta-
neous high frequency motor unit action potentials,
which resembled discharges seen in neuromyotonia,
were detectable on EMG testing on days 2 to 4 post-
treatment with the muscle clinically at rest indepen-
dently of EMG needle insertion. They were detected in
100% of patients and 72% of muscles on days 2 to 4
after treatment with oxaliplatin plus capecitabine but in
none of the patients or muscles tested before oxaliplatin
treatment or after treatment with carboplatin plus pacli-
taxel or cisplatin. Abnormal, spontaneous high fre-
quency motor unit activity was more frequent on days 2
to 4 than on days 14 to 20 post-treatment, and was
more sensitive and more specific than repetitive CMAPs
for detecting acute oxaliplatin-induced motor nerve
hyperexcitability. Repetitive CMAPs were abnormal
action potentials occurring after a single electrical sti-
mulus following the main CMAP. These findings con-
firm a previous report [5,6] of spontaneous high
frequency motor unit action potentials and repetitive
CMAPs after oxaliplatin treatment and refined clinical
procedures for the neurophysiological assessment of
chemotherapy-induced motor nerve hyperexcitability.
The neurophysiological features of acute oxaliplatin-
induced motor nerve hyperexcitability found in this
study, and those described previously [5,6] are similar to
those seen in acquired neuromyotonia. Neuromyotonia
is often associated with autoantibodies against potassium
channels [7], and it has been postulated that disruption
of K
+ channels is a key element in the production of
neuromyotonia. However, in a mouse diaphragm model,
K
+ channel blockade did not replicate the neurophysio-
logical features of oxaliplatin[8]. Instead, the increase in
spontaneous activity induced by oxaliplatin in this
model was prevented by the voltage-gated Na
+ channel
blocker tetrodotoxin. The authors concluded that the
most likely mechanism of oxaliplatin neurotoxicity is a
direct effect on voltage-gated Na
+ channels rather than
an effect on K
+ channels or nerve terminal Ca
2+ regula-
tion. Others have also found evidence of Na
+ channel
dysfunction with oxaliplatin use [9,10] although this has
not been a consistent finding [11].
Repetitive CMAPs may be generated at the synapse or
i nt h em o t o rn e r v ea x o n[ 1 2 ] .S y n a p t i cC M A P sm a y
occur when there is excessive acetyl choline (ACh) in
the synapse, and they can also occur with normal
amounts of ACh in the synapse in the slow channel syn-
drome [13]. There is no reason to suppose that repeti-
tive CMAPs in the setting of oxaliplatin use are due to
excessive ACh in the synapse. Instead, the repetitive
CMAPs that were observed following a single electrical
stimulus were almost certainly generated in the motor
nerve axons themselves. Repetitive CMAPs similar to
those recorded here have been described in neuromyo-
tonia,[12] and the authors concluded from their studies
that the focus of abnormal excitation must have been in
the distal part of the nerve. Presumably disruption of
function of sodium channels is also the reason for the
appearance of the repetitive CMAPs with oxaliplatin
use, as well as causing the spontaneous high frequency
motor unit activity seen on EMG.
Neurophysiological studies are more subjective than
may be appreciated, and for this reason considerable
lengths were taken to eliminate bias from the current
study by including relevant control groups and ensuring
the neurophysiologist was blinded to the treatment
group and patient details. In particular, determining
whether there is abnormal insertional EMG activity is
very subjective, and this is likely to have contributed to
false positive tests recorded in control patients. How-
ever, the more robust finding of abnormal spontaneous
high frequency motor unit activity was not detected in
any of the control patients who were tested before
receiving oxaliplatin or after other chemotherapeutic
agents. Similarly, it was difficult at times to determine
whether there were one or more abnormal repetitive
CMAPs following a single stimulus, and whether this
had occurred because some patients were not ade-
quately relaxed for testing. However, the impression was
that repetitive CMAPs were much more prominent after
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not possible to devise any method for quantifying this
abnormality to improve its specificity.
Motor nerve hyperexcitability with subsequent abnor-
mal muscle contraction could be a basis for some of the
acute neurotoxicity symptoms reported by patients after
oxaliplatin treatment. Approximately 70% of patients
treated with oxaliplatin in the current study complained
of jaw or throat tightness, and 4 of 22 patients reported
muscle cramps. However, motor symptoms occurred
less frequently than abnormal, spontaneous high fre-
quency motor unit activity as determined by EMG
assessment of subclinical motor nerve hyperexcitability.
Cold-induced paraesthesiae were reported universally by
oxaliplatin-treated patients in the current study, with or
without other sensory symptoms, which may be due to
sensory nerve hyperexcitability that was undetectable by
conventional neurophysiological testing.
Park et al [9] found evidence of sensory nerve hyper-
excitability and functional channelopathy of axonal
sodium channels when they undertook axonal excitabil-
ity studies in 58 patients who were treated with oxalipla-
tin. Significant changes were evident in both sensory
and motor axons in recovery cycle parameters immedi-
ately following oxaliplatin infusions. The extent of oxali-
platin-induced abnormality in motor axons was
proportional to the degree of change in sensory axons.
Abnormalities became progressively worse in sensory
axons, while motor axonal excitability remained
unchanged with repeated doses of oxaliplatin. Sensory
excitability abnormalities that developed during early
treatment cycles were able to predict the development
of chronic sensory neuropathy on an individual patient
basis in 80% of patients, in their study. The neurophy-
siological studies undertaken by Park et al [9] were
notably different from those performed in the current
study. Their studies required specialised equipment, but
our studies comprised conventional clinical neurophy-
siological studies, and included detailed EMG studies.
As such, the studies are complementary. The testing in
the current study, which was less sophisticated than that
undertaken by Park et al [9], did not identify sensory
abnormalities acutely, but found clear evidence of motor
nerve excitability acutely that resolved over subsequent
weeks.
Finally, our study suggests that the mechanism of
acute oxaliplatin-induced motor nerve hyperexcitability
differs from the mechanisms involved in the chronic
neuro-sensory toxicities of oxaliplatin and related che-
motherapeutic agents. We showed evidence of acute
motor nerve hyperexcitability on nerve conduction stu-
dies and EMG after oxaliplatin treatment, but not fol-
lowing treatment with carboplatin plus paclitaxel or
cisplatin. In contrast, cisplatin, carboplatin plus
paclitaxel and oxaliplatin are well known for inducing
chronic neuro-sensory toxicity in a high percentage of
treated patients that typically present with chronic
neuro-sensory symptoms and loss of sensation with
motor function spared [2,3,14]. Differences between the
acute and chronic neurotoxicity profiles of different che-
motherapy drugs, and in their relative specificity for
inducing toxicity to peripheral sensory versus motor
nerves, suggests that these are distinct and mechanisti-
cally unrelated neurotoxicities. The mechanisms of
acute and chronic neurotoxicities of platinum drugs are
unknown. However, acute motor nerve hyperexcitability
induced by oxaliplatin may be due to chelation of cal-
cium or other endogenous divalent cations by its oxalate
leaving group [15], but not by the leaving groups of
other platinum drugs. In contrast, the chronic neuro-
sensory toxicities of cisplatin, carboplatin and oxaliplatin
maybe due to neuronal accumulation of platinum [16],
which is a common element of all chemotherapeutic
agents of the class.
Conclusions
Abnormal, spontaneous high frequency motor fibre
activity is a sensitive and specific endpoint of acute oxa-
liplatin-induced motor nerve hyperexcitability, detect-
able on EMG on days 2 to 4 post-treatment. Objective
EMG assessment of motor nerve excitability could com-
pliment patient-reported symptomatic endpoints of
acute oxaliplatin-induced neurotoxicity in future studies,
and is suitable for use in multicentre clinical trials as
EMG is widely available as a routine diagnostic clinical
procedure.
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